Phase 3 study of DARE-HRT1 in patients with moderate-to-severe Vasomotor Symptoms (VMS) due to Menopause
Latest Information Update: 14 Aug 2023
At a glance
- Drugs Estradiol/progesterone (Primary)
- Indications Menopausal syndrome; Vasomotor symptoms
- Focus Registrational; Therapeutic Use
Most Recent Events
- 14 Aug 2023 New trial record
- 09 Aug 2023 According to a Dare Bioscience media release, the company intends to seek FDA approval of DARE-HRT1 for the treatment of moderate-to-severe VMS due to menopause in women with intact uteri.
- 09 Aug 2023 According to a Dare Bioscience media releas, the company Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of VMS due to Menopause.